ROVI updates its strategy in a meeting with shareholders, investors and analysts
Mar, 16/11/2021 - 14:31
1 minROVI updates its strategy in a meeting with shareholders, investors and analysts
Relacionados
Al cierre de los nueve primeros meses de 2022
ROVI AUMENTA UN 25% SU EBITDA Y ALCANZA LOS 173,9 MILLONES DE EUROS
La farmacéutica...
8 min
04/11/2022
A la visita de la planta, que ya se encuentra lista para poder producir una vez reciba la autorización de la AEMPS, han asistido también...
4 min
24/10/2022
Nace Glicopepton Biotech para producir compuestos de alto valor tecnológico
· ROVI, Càrniques Celrà y Grupo Costa anuncian la...
3 min
04/10/2022
shutterstock_1323088832.jpg
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)
Madrid, 16 November 2021
In compliance with the reporting requirements provided for in article 227 of the consolidated text of the Securities Market Act, ROVI sends and publishes the attached presentation regarding the update of the company strategy, a presentation that will be distributed today and which can be accessed through the website of the company. Likewise, ROVI will hold a virtual meeting today with analysts and investors to present said presentation.
Mr. Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.